| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico. 
|
|
Today’s Big NewsMay 21, 2024 |
|
Thursday, June 6, 2024 | 11am ET / 7am PT Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. Join us for a look at the new alternatives for success. Register now. 
|
|
| By Zoey Becker The Senator inked a letter to Pfizer's CEO asking for information relating to the sharp drop in the company's effective tax rate since the passage of former president Donald Trump's 2017 tax law. |
|
|
|
By James Waldron AstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy strategy, CEO Pascal Soriot told investors as he set out a bold ambition to almost double global revenues to $80 billion by 2030. |
By Kevin Dunleavy After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again. On Tuesday morning, AZ unveiled its new plan to swell its revenue to $80 billion by 2030. |
By Nick Paul Taylor A survey has shown the demographics most likely to be distrustful of the FDA. The results suggest the agency needs to win the trust of conservative women in rural communities who are in poor health or dissatisfied with their healthcare. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now. 
|
|
By Conor Hale Johnson & Johnson MedTech’s Biosense Webster division presented new clinical data backing up its pulsed field ablation approach for treating atrial fibrillation, which was submitted for FDA review earlier this year. |
By Annalee Armstrong Exscientia is initiating “efficiency measures” to save cash, which will include a workforce reduction of around a quarter of staff while preserving the AI drug hunter’s existing pipeline. |
By Zoey Becker A newly unsealed complaint from the laboratory that first revealed Zantac's links to a carcinogenic impurity lays out a web of allegations about GSK's efforts to bring the drug to market in the 1980s and its attempts to hide the risks since then. |
By Andrea Park Nearly a decade into Cosentyx’s tenure as an FDA-approved treatment for plaque psoriasis and psoriatic arthritis, Novartis has tapped two of its go-to celebrity spokespeople to confirm that the drug is still working for them. |
By Nick Paul Taylor Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets. |
By Fraiser Kansteiner Following last year’s hard-won ulcerative colitis nod for Eli Lilly’s Omvoh, also known as mirikizumab, the Indianapolis-based drugmaker is padding the case for its antibody’s next potential immunology approval. |
By Conor Hale The test is designed to be performed between 11 and 14 weeks into pregnancy and delivers a risk score for developing the condition before 34 weeks. |
By Nick Paul Taylor The pharma industry is still in HCPs’ good books, with 61% of physicians polled by CMI saying they have a favorable view of drugmakers. But the question of how companies can use corporate brand marketing to promote and enhance their image is more vexed given HCPs’ mixed views on the subject. |
By Gabrielle Masson It’s not a double album release, but a close runner-up: The pivotal SWIFT-1 and SWIFT-2 trials have both shown GSK's long-acting asthma treatment reduces attacks. |
By Ben Adams South Korean biosimilar company Celltrion is signing up Mollie Pearce, a contestant on the British TV show “The Traitors,” to help front its latest “Where’s Crohn’s & Colitis?” campaign. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us on Monday, June 19, 2024 for one hour all about oral cyclic peptide drug development. Smaller breakthroughs in our own labs demonstrate results worth registering for. 
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
